Ovarian Cancer Clinical Trial
Official title:
A Phase 1/2a Evaluation of the Safety, Pharmacokinetics and Efficacy of AL3818, a Dual Receptor Tyrosine Kinase Inhibitor, in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001)
The purpose of Part 1 (Phase 1b) is to evaluate the general safety and tolerability of
repeated 21-day cycles of AL3818 therapy, and to reevaluate the maximum tolerated dose (MTD).
The purpose of Part 2 (Phase 2a) is to evaluate the efficacy of repeated 21-day cycles of
AL3818 therapy preliminary efficacy of AL3818 in subjects with recurrent or metastatic
endometrial, ovarian or cervical cancer.
This is a Phase 1b/2a study to evaluate the safety, pharmacokinetics and efficacy of 21-day
cycles of AL3818 therapy. The study is divided into two parts. Part 1 (Phase 1b) will
evaluate the dose limiting toxicity (DLT) and general safety during the first 21-day cycle of
Al3818 therapy and to reevaluate the MTD. It will include a sequential evaluation of 3
subjects per cohort in a 3+3 design with up to 18 subjects in total. Cohort 1 will initiate
at a dose of 12 mg/day of AL3818, for cycles of 14 days of treatment followed by 7 days of
rest. After three subjects have completed the first cycle of therapy without a DLT,
additional cohorts may be enrolled sequentially. All subjects will be allowed continuation of
therapy with repeat cycles of 21-days if they are tolerating AL3818 and have stable disease
or better. After the first cohort has completed one full cycle of therapy without a DLT, two
additional cohorts will be sequentially enrolled at 16 mg/day and 20 mg/day doses of AL3818
for the same 21-day cycles.
Part 2 (Phase 2a) will evaluate the safety and preliminary efficacy of repeated 21-day cycles
of AL3818. It will include up to 45 additional subjects with metastatic endometrial cancer,
ovarian cancer refractory to platinum therapy or cervical cancer refractory to standard
therapy. Each subject will receive a dose of up to 20 mg AL3818 or a maximum of the MTD from
Part 1 (Phase 1b) of this study for continuous 21-Day cycles of therapy (14 days of AL3818
treatment followed by 7 days off).
All subjects in Part 1 and Part 2 of this study will be permitted to continue therapy with
only safety monitoring and bimonthly assessments for progression, if AL3818 is well tolerated
and the subject has stable disease or better.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
| Withdrawn |
NCT05201001 -
APX005M in Patients With Recurrent Ovarian Cancer
|
Phase 2 | |
| Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
| Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
| Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
| Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05156892 -
Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer
|
Phase 1 | |
| Suspended |
NCT02432378 -
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04533763 -
Living WELL: A Web-Based Program for Ovarian Cancer Survivors
|
N/A | |
| Active, not recruiting |
NCT03371693 -
Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer
|
Phase 3 | |
| Withdrawn |
NCT03032614 -
Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients
|
Phase 2 | |
| Completed |
NCT01936363 -
Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer
|
Phase 2 | |
| Completed |
NCT02019524 -
Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients
|
Phase 1 | |
| Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05059522 -
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
|
Phase 3 | |
| Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
| Terminated |
NCT04586335 -
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
|
Phase 1 | |
| Terminated |
NCT03146663 -
NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer
|
Phase 2 |